A detailed history of Lindbrook Capital, LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 319 shares of CGEM stock, worth $4,290. This represents 0.0% of its overall portfolio holdings.

Number of Shares
319
Previous 291 9.62%
Holding current value
$4,290
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$16.03 - $20.86 $448 - $584
28 Added 9.62%
319 $5,000
Q4 2023

Jan 31, 2024

BUY
$7.89 - $10.23 $2,295 - $2,976
291 New
291 $2,000
Q2 2023

Jul 28, 2023

SELL
$8.8 - $13.4 $2,050 - $3,122
-233 Reduced 60.21%
154 $1,000
Q1 2023

Apr 26, 2023

BUY
$10.2 - $11.91 $20 - $23
2 Added 0.52%
387 $3,000
Q4 2022

Jan 24, 2023

BUY
$9.72 - $13.62 $2,012 - $2,819
207 Added 116.29%
385 $0
Q2 2022

Aug 01, 2022

BUY
$7.31 - $13.55 $241 - $447
33 Added 22.76%
178 $2,000
Q1 2022

Apr 21, 2022

BUY
$10.47 - $16.75 $1,518 - $2,428
145 New
145 $2,000

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $613M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.